<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03504527</url>
  </required_header>
  <id_info>
    <org_study_id>KY2017-008</org_study_id>
    <nct_id>NCT03504527</nct_id>
  </id_info>
  <brief_title>Efficiency of Budesonide Combined With Formoterol and Tiotropium in the Treatment of Acute Exacerbation of ACO</brief_title>
  <official_title>Effeciency of Budesonide Combined With Formoterol and Tiotropium in the Treatment of Acute Exacerbation of Asthma-chronic Obstructive Pulmonary Overlap: A Randomized Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficiency of ICS(budesonide) combined with LABA (formoterol) and
      LAMA(tiotropium) in the treatment of acute exacerbation of asthma-chronic obstructive
      pulmonary overlap. Half of participants will receive budesonide,formoterol and tiotropium in
      combination, while the other half will receive budesonide and formoterol only.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ACO(asthma-chronic obstructive pulmonary overlap) is a relatively new proposed clinical form
      of chronic airway disease. Guideline or preferring therapy for ACO is still evolving. Current
      clinical solution is when ACO presents like asthma, initial treatment will accord to the
      guideline for asthma , while it presents like COPD, COPD recommendation treatment (not alone
      ICS,but ICS in addition of LABA with or without LAMA) will be chosen, which are subjective.
      Although present guidelines has recommended that ACO should be treated with at last two
      inhalant, but limited date have proven it.

      A random controlled trial will be conducted to evaluate the efficiency of ICS(budesonide)
      combined with LABA (formoterol) and LAMA(tiotropium bromide) in the treatment of acute
      exacerbation of ACO,compared with the control group receiving tiotropium bromide with
      formoterol only.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the frequency of ACO exacerbation</measure>
    <time_frame>12 months</time_frame>
    <description>the frequency of ACO exacerbation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postbronchodilator FEV1</measure>
    <time_frame>12 months</time_frame>
    <description>a post-bronchodilator forced expiratory volume in one second</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>times of hospital readmission caused by exacerbation</measure>
    <time_frame>12 months</time_frame>
    <description>times of hospital readmission caused by exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>other lung function parameters</measure>
    <time_frame>12 months</time_frame>
    <description>other lung function parameters(%FEV1, FEV1/FVC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCQ score</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical COPD Questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mMRC score</measure>
    <time_frame>12 months</time_frame>
    <description>modified Medical Research Council score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAT score</measure>
    <time_frame>12 months</time_frame>
    <description>COPD Assessment Test score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACT score</measure>
    <time_frame>12 months</time_frame>
    <description>Asthma Control Test score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Asthma-COPD Overlap</condition>
  <arm_group>
    <arm_group_label>triple combinations</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide/Fermotil inhalant 160ug/4.5ug bid; Tiotropium bromide inhalants 18ug qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>double combinations</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fermotil inhalants 4.5ug bid; Tiotropium bromide inhalants 18ug qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triple combinations</intervention_name>
    <description>inhaled budesonide(160ug,bid),formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)</description>
    <arm_group_label>triple combinations</arm_group_label>
    <other_name>budesonide/formotero/tiotropium bromide triple combinations</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>double combinations</intervention_name>
    <description>inhaled formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)</description>
    <arm_group_label>double combinations</arm_group_label>
    <other_name>formotero/tiotropium bromide double combinations</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subject has ACO

        Exclusion Criteria:

          -  acute exacerbation of ACO;

          -  acute infection;

          -  postbrochodilator FEV1/FVC&gt; 0.7;

          -  pulmonary complications: bronchiectasis, active tuberculosis, pulmonary fungal disease
             or lung cancer

          -  history of other malignant tumor

          -  with rheumatic diseases;

          -  with some serious heart, cerebrovascular, liver, kidney or hematopoietic system
             diseases

          -  with tachyarrhythmias；

          -  mental patients;

          -  with moderate to severe renal insufficiency (creatinine clearance ≤ 50ml / h)

          -  allergic to the budesonide, formoterol or tiotropium bromide;

          -  history of acute gastrointestinal bleeding within 3 months;

          -  with severe angle closure glaucoma patients;

          -  pregnancy,lactation;

          -  have participated in other clinical trials in 3 months；

          -  hospital staff and their relatives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Shengqing, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Shengqing, PhD</last_name>
    <phone>+86-02150887072</phone>
    <email>shengqingli@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhang Xia, PhD</last_name>
    <phone>+86-02150887073</phone>
    <email>xiangruye@126.com</email>
  </overall_contact_backup>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2018</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Shengqing Li</investigator_full_name>
    <investigator_title>Chief physician, professor</investigator_title>
  </responsible_party>
  <keyword>ICS</keyword>
  <keyword>LABA</keyword>
  <keyword>LAMA</keyword>
  <keyword>therapy</keyword>
  <keyword>asthma</keyword>
  <keyword>COPD</keyword>
  <keyword>ACO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

